$2.84
2.53% yesterday
Nasdaq, Dec 24, 10:58 pm CET
ISIN
US81642T1007
Symbol
SLS

SELLAS Life Sciences Group, Inc. Stock price

$2.84
+1.29 83.23% 1M
+1.07 60.45% 6M
+1.80 173.08% YTD
+1.91 205.54% 1Y
+0.57 25.11% 3Y
-3.47 54.99% 5Y
-45,897.16 99.99% 10Y
-5.87 67.39% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.07 2.53%
ISIN
US81642T1007
Symbol
SLS
Industry

Key metrics

Basic
Market capitalization
$404.5m
Enterprise Value
$360.2m
Net debt
positive
Cash
$44.3m
Shares outstanding
125.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
8.9
Financial Health
Equity Ratio
48.7%
Return on Equity
-327.5%
ROCE
-59.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-26.9m | $-29.0m
Net Income
$-25.9m | $-33.5m
Free Cash Flow
$-30.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
17.8% | 9.2%
Net Income
19.6% | -8.0%
Free Cash Flow
7.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
23.5%
Employees
15
Rev per Employee
$0.0
Show more

Is SELLAS Life Sciences Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

SELLAS Life Sciences Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

Buy
86%
Hold
14%

Financial data from SELLAS Life Sciences Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
14% 14%
-
- Research and Development Expense 16 16
20% 20%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -27 -27
18% 18%
-
Net Profit -26 -26
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about SELLAS Life Sciences Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SELLAS Life Sciences Group, Inc. Stock News

Neutral
GlobeNewsWire
18 days ago
NEW YORK, Dec. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that clinical data from its ongoing Phase 2 study of SLS009, a highly selective CDK9 inhibitor, in combination with azacitidi...
Neutral
Seeking Alpha
about 2 months ago
SELLAS Life Sciences Group, Inc. ( SLS ) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs October 29, 2025 10:00 AM EDT Company Participants Angelos Stergiou - Founder, President, CEO & Director Dragan Cicic - Senior VP & Chief Development Officer Conference Call Participants Dr. Omer Jamy Dr. Panagiotis Tsirigotis Dr. Philip M. Ryan Sharif Khan, M.D.
Neutral
GlobeNewsWire
about 2 months ago
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exercise of warrants, previously issued in March and August 2024 (the “Existing Warrants”), to purchase up to 22...
More SELLAS Life Sciences Group, Inc. News

Company Profile

SELLAS Life Sciences Group, Inc. engages in the development and commercialization of immunotherapeutics for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Head office United States
CEO Angelos Stergiou
Employees 15
Founded 2006
Website www.sellaslifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today